Beyondspring Stock

Beyondspring EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Beyondspring (BYSI) as of Jul 17, 2026 is -5.97. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -3.46 — a change of 72.28% (lower).

EV/EBIT

-5.97

YoY

72.28%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Beyondspring is 2026 -5.97 . EV/EBIT (Enterprise Value to EBIT) of Beyondspring was 2025 -3.46 . It decreases by 72.28% lower compared to the previous year.

The Beyondspring EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-7.39 base
Jan 1, 2019
-9.48 base
Jan 1, 2020
-5.70 base
Jan 1, 2021
-2.67 base
Jan 1, 2022
-1.97 base
Jan 1, 2023
-2.33 base
Jan 1, 2024
-7.40 base
Jan 1, 2025 (e)
-1.41 base
YEARPRICE-TO-EBIT
2025 est -1.41
2024 -7.40
2023 -2.33
2022 -1.97
2021 -2.67
2020 -5.70
2019 -9.48
2018 -7.39
2017 -6.19
2016 -
2015 -
2014 -
Access this data via the Eulerpool API

Beyondspring Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Beyondspring's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Beyondspring's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Beyondspring's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Beyondspring grows earnings faster than its peers.

Beyondspring Stock analysis

What does Beyondspring do? Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes. Beyondspring is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beyondspring stock

EV/EBIT (Enterprise Value to EBIT) of Beyondspring is -5.97 in 2026.

Access this data via the Eulerpool API

Valuation — Beyondspring

All Key Metrics — Beyondspring